SCHEMBL4483488

SCHEMBL4483488

CC(C(=O)c1ncc[nH]1)c1cccc(C(=O)c2ccccc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.58
PTGS1 P23219 4/20 0.58
PTGS2 P35354 4/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
ALDH1A1 P00352 3/20 0.58
LMNA P02545 3/20 0.58
CXCR1 P25024 2/20 0.58
CXCR2 P25025 2/20 0.58
CYP3A4 P08684 2/20 0.58
RECQL P46063 1/20 0.58
KDM4E B2RXH2 1/20 0.58
HPGD P15428 1/20 0.58
MAPK1 P28482 1/20 0.58
PMP22 Q01453 1/20 0.58
SLC22A6 Q4U2R8 1/20 0.58
HSD17B10 Q99714 1/20 0.58
CXCL8 P10145 1/20 0.58
THPO P40225 1/20 0.58
HIF1A Q16665 1/20 0.58
HTT P42858 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9057032 0.80 PTGS1 (0.60) MAPTPTGS1PTGS2SMN1; SMN2ALDH1A1
Ketoprofen SCHEMBL679920 0.75 PTGS1 (1.00) MAPTPTGS1PTGS2SMN1; SMN2ALDH1A1
R-Ketoprofen SCHEMBL29353694 0.75 PTGS1 (1.00) MAPTPTGS1PTGS2SMN1; SMN2ALDH1A1
Dexketoprofen SCHEMBL66987 0.75 PTGS1 (1.00) MAPTPTGS1PTGS2SMN1; SMN2ALDH1A1
Ketoprofen SCHEMBL3843886 0.75 PTGS1 (1.00) MAPTPTGS1PTGS2SMN1; SMN2ALDH1A1
Dexketoprofen SCHEMBL29396875 0.75 PTGS1 (1.00) MAPTPTGS1PTGS2SMN1; SMN2ALDH1A1
R-Ketoprofen SCHEMBL195303 0.75 PTGS1 (1.00) MAPTPTGS1PTGS2SMN1; SMN2ALDH1A1
Ketoprofen SCHEMBL8754790 0.75 PTGS1 (1.00) MAPTPTGS1PTGS2SMN1; SMN2ALDH1A1
Ketoprofen SCHEMBL16757741 0.75 PTGS1 (1.00) MAPTPTGS1PTGS2SMN1; SMN2ALDH1A1
Ketoprofen SCHEMBL8577572 0.75 PTGS1 (1.00) MAPTPTGS1PTGS2SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9328057-B2 Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases DOMPE' FARMACEUTICI S.P.A. (IT) 2016-05-03 US disclosed
US-20090203652-A1 CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES DOMPE PHA.R.MA S.P.A. (IT) 2009-08-13 US disclosed
EP-1581474-B1 CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES DOMPE SPA (IT) 2008-08-27 EP disclosed
US-20060247297-A1 Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases DOMPE PHA.R.MA S.P.A. (IT) 2006-11-02 US disclosed
EP-1581474-A1 CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES Dompé S.P.A. (IT) 2005-10-05 EP disclosed
WO-2004052830-A1 CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES DOMPE S.P.A. (IT) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247297-A1 Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases NR1H4, MMP8, NR1I2 MAPT 1794/4885PTGS1 664/4885PTGS2 803/4885
US-20090203652-A1 CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES NR1H4, MMP8, NR1I2 MAPT 1794/4885PTGS1 664/4885PTGS2 803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.